Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06792994 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06792994 · ClinicalTrials.gov record · last posted 2026-04-30

A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG

Study acronym: CLL2000
StatusRecruiting
PhaseNot specified
Started2026-04-02
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This observational trial is designed to investigate long-term survival with regard to the primary endpoint overall survival (OS) after start of first-line treatment.

Amendment record 3 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 3 times since 2025-01-20; most recent amendment 2026-04-27. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2026-04-27
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT06792994
Lead Sponsor German CLL Study Group
Collaborators: GELLC (Grupo Español de Leucemia Linfocítica Crónica), Nordic Lymphoma Group, Polish Adult Leukemia Group, HOVON - Dutch Haemato-Oncology Association
Conditions Chronic Lymphocytic Leukemia
Enrollment 2,000 participants
Start Date 2026-04-02
Primary Completion 2030-08-01 (estimated)
Study Completion 2030-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-30